Global Eating Disorders (EDs) Market Competitive Analysis 2026 By Omeros Corporation, KUHNIL, Sunovion Pharmaceuticals, Inc., Alkermes, Takeda Pharmaceutical Company Limited, Abbott, Novo Nordisk A/S & others
This eating disorders market report also estimates the growth rate and the market value based on market dynamics and growth inducing factors. It is a well-versed fact that competitive analysis is the major aspect of any market research report and hence many points are covered under this including strategic profiling of key players in the market, analyse core competencies of key players, and draw a competitive landscape for the market. This eating disorders report is built with the careful efforts of innovative, enthusiastic, knowledgeable and experienced team of analysts, researchers, industry experts, and forecasters.
Global Eating Disorders (EDs) Market By Type (Anorexia Nervosa, Bulimia Nervosa, Binge Eating Disorder, Pica, Rumination Disorder, Avoidant or Restrictive Food Intake Disorder, Others), Drugs (Antidepressants, Antipsychotics, Calcium Plus Vitamin D Supplement, Gastrointestinal Stimulants, Others), End User (Hospitals, Clinics, Others), Distribution Channel (Direct, Retail), Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa) – Industry Trends and Forecast to 2026
Get Sample Copy Of This Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-eating-disorders-eds-market
Global eating disorders (EDs) market is expected to rise with a substantial CAGR in the forecast period of 2019-2026. This rise in market value can be attributed to the increasing cases of patients suffering from anorexia and bulimia. The report contains data from the historic year of 2017, base year of 2018.
Few of the major competitors currently working in the global eating disorders (EDs) market are GlaxoSmithKline plc., INSYS THERAPEUTICS, INC, Omeros Corporation, KUHNIL, Sunovion Pharmaceuticals, Inc., Alkermes, Takeda Pharmaceutical Company Limited, Abbott, Novo Nordisk A/S, Sanofi, Eisai Co., Ltd., Jazz Pharmaceuticals, Inc., Eli Lilly and Company., F. Hoffmann-La Roche Ltd, Amgen Inc., Nestlé, BioGaia AB, Johnson & Johnson Services, Inc., Cannabics Pharmaceuticals Inc., Bristol-Myers Squibb Company among others.
Segmentation: Global Eating Disorders (EDs) Market
By Type
- Anorexia Nervosa
- Bulimia Nervosa
- Binge Eating Disorder
- Pica
- Rumination Disorder
- Avoidant or Restrictive Food Intake Disorder
- Others
By Drugs
- Antidepressants
- Antipsychotics
- Calcium Plus Vitamin D Supplement
- Gastrointestinal Stimulants
- Others
By End-User
- Hospitals
- Clinics
- Others
By Distribution Channel
- Direct
- Retail
By Geography
- North America
- Europe
- Asia-Pacific
- South America
- Middle East and Africa
Inquiry For Customize Report With Discount at : https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-eating-disorders-eds-market
Market Drivers:
- Increasing cases of patients suffering from anorexia and bulimia is expected to drive the growth of the market
- Genetics, unusual level of biochemical in the body is expected to drive the growth of the market
- Rising stress is expected to drive the growth of the market
- Psychological and environmental factors is also expected to boost the growth of the market
Market Restraints:
- Stringent regulatory policies can also act as a restricting factor for this market growth
- Limited operating revenue opportunities for research and development of targeted therapies by many pharmaceuticals is acting as a challenging factor for the growth of this market
- Low healthcare budget in some developing countries is hamper the market growth
Key Developments in the Market:
- In July 2019, Sunovion Pharmaceuticals, Inc. received FDA approval for its dasotraline which can used to treat of moderate to severe binge-eating disorder. Dasotraline is a dopamine and norepinephrine reuptake inhibitor. This product approval has created a milestone for the company
- In June 2019, Shire (A subsidiary of Takeda Pharmaceutical Company) received FDA’s extended approval for its Vyvanse (lisdexamfetamine dimesylate). This drug is used for the treatment of binge-eating disorder in adults. This product approval will expand the company’s product portfolio for the market
Competitive Analysis
Global eating disorders (EDs) market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of eating disorders (EDs) market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.
Get Detailed TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-eating-disorders-eds-market
About Data Bridge Market Research
An absolute way to forecast what future holds is to comprehend the trend today!
Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.
Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.
Contact:
Data Bridge Market Research
Tel: +1-888-387-2818
Email: [email protected]
